Audentes Therapeutics, Inc. SEC Filings

Filed On	Filing
31 Oct 2022	Form 3: Audentes Therapeutics, Inc., 10% owner and 1 other · Taysha Gene Therapies, Inc. Holds 7,266,342 shares of Common Stock
31 Oct 2022	SC 13D
14 Feb 2020	SC 13G/A
14 Feb 2020	SC 13G/A
14 Feb 2020	SC 13G/A
11 Feb 2020	SCHEDULE 13G
05 Feb 2020	SC 13G/A
27 Jan 2020	15-12B
17 Jan 2020	EFFECT
17 Jan 2020	EFFECT
15 Jan 2020	8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +6 more
15 Jan 2020	Form 4: Soloway Thomas P, Executive Vice President, CFO Disposed of 183,384 shares (Tender Offer) ($11M) · Disposed of 223,873 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Smith Julie, Director Disposed of 53,200 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Schuetz Thomas J., Director Disposed of 89,695 shares (Tender Offer) ($5.38M) · Disposed of 67,891 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Patterson Matthew R, Director Disposed of 433,272 shares (Tender Offer) ($26M) · Disposed of 734,353 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Mosbrooker Eric, SVP, Chief Commercial Officer Disposed of 26,919 shares (Tender Offer) ($1.62M) · Disposed of 87,750 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Morrison Scott W, Director Disposed of 77,835 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Meltz Mark A, SVP, General Counsel Disposed of 32,705 shares (Tender Offer) ($1.96M) · Disposed of 104,000 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Lange Louis G, Director Disposed of 315,375 shares (Tender Offer) ($18.9M) · Disposed of 53,200 Stock Option (Right to Buy) (Disposition to Issuer)
15 Jan 2020	Form 4: Jarrett Jennifer, Director Disposed of 53,200 Stock Option (Right to Buy) (Disposition to Issuer)

Comments